Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
PHASE2CompletedINTERVENTIONAL
Enrollment
41
Participants
Timeline
Start Date
April 30, 2003
Primary Completion Date
December 31, 2009
Study Completion Date
November 30, 2013
Conditions
Adenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachIntestinal Adenocarcinoma of the StomachMixed Adenocarcinoma of the StomachRecurrent Gastric CancerStage IIIB Gastric CancerStage IIIC Gastric CancerStage IV Gastric Cancer
Interventions
DRUG
bortezomib
Given IV
DRUG
irinotecan
Given IV
Trial Locations (1)
10467-2490
Montefiore Medical Center, The Bronx
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00061932 - Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach | Biotech Hunter | Biotech Hunter